GLP-1 receptor agonist weight-loss drugs such as semaglutide may protect the cardiovascular system independent of weight loss.
“In contrast, reductions in waist circumference at 20 weeks were associated with fewer subsequent events in the semaglutide group, possibly highlighting the importance of visceral fat loss (fat surrounding abdominal organs) rather than overall weight loss, which can also include lean mass such as muscle.”